Vaxcyte Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-436.82	-402.27	-223.49	-100.08	-89.22	-50.27	Upgrade
Depreciation & Amortization	10.92	10.17	9.2	3.46	1.41	1.23	Upgrade
Share-Based Compensation	56.74	48.76	23.65	10.73	5.43	1.19	Upgrade
Other Operating Activities	-39.06	46.55	20.04	-35.5	35.75	0.71	Upgrade
Operating Cash Flow	-408.22	-296.79	-170.6	-121.39	-46.63	-47.15	Upgrade
Capital Expenditures	-74.34	-67.88	-5.84	-6.53	-1.11	-1.2	Upgrade
Change in Investments	-701.94	-705.43	80.43	-205.78	0	0	Upgrade
Investing Cash Flow	-776.28	-773.31	74.59	-212.31	-1.11	-1.2	Upgrade
Share Issuance / Repurchase	1,416	639.81	861.55	17.8	265.05	0.44	Upgrade
Debt Issued / Paid	0	0	0	0	-0.06	-0.28	Upgrade
Other Financing Activities	-	-	-	-	109.88	41.4	Upgrade
Financing Cash Flow	1,416	639.81	861.55	17.8	374.87	41.57	Upgrade
Exchange Rate Effect	-0.65	-6.69	0.14	-0.44	0.09	-0.34	Upgrade
Net Cash Flow	231.29	-436.97	765.67	-316.34	327.22	-7.11	Upgrade
Free Cash Flow	-482.56	-364.67	-176.44	-127.92	-47.73	-48.34	Upgrade
Free Cash Flow Per Share	-4.32	-3.75	-2.72	-2.46	-1.62	-12.74	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).